Abstract
Study Design
Retrospective Cohort Study.
Objective
Reconstruction of maxillary bone defects can be completed with vascularized and non-vascularized autografts. Cellular bone matrix allografts (CBMs), which have lineage committed bone cells, has risen as an alternative. The purpose of this study was to describe our experience and to determine the success of CBM based maxillary reconstruction in a variety of clinical scenarios.
Methods
A retrospective cohort study was designed and implemented using data from subjects who presented to the University of Louisville and were treated with a CBM for maxillary reconstruction from 2019 to 2023. Subjects were excluded if they were not treated with a CBM, data were not complete, or postoperative follow-up time was less than 3 months. Descriptive statistics were calculated for each variable. To measure the associations between the risk factors and graft success, Fisher’s exact test was implemented. A P-value of <0.05 was considered significant.
Results
The sample included 48 subjects. The mean age of all subjects was 43 ± 24 years. Overall, 42 (87.5%) cases were successful. The perioperative antibiotic administered (P = 0.02), etiology (P = 0.021), and the addition of platelet rich fibrin or autograft as an adjunct influenced CBM success (P = 0.039).
Conclusions
CBMs are a viable option for reconstruction of maxillary bone defects. CBMs may be an alternative to autografts.
Get full access to this article
View all access options for this article.